B细胞血液肿瘤患者外周血CD40、CD154的表达及意义

目的 分析B细胞血液肿瘤外周血淋巴细胞CD40、CD154表达率的特点。方法 28例B细胞血液肿瘤患者分为多发性骨髓瘤（Multiple Myeloma,MM）17例,B细胞性非霍奇金淋巴瘤（B-NHL）11例;选取30例健康体检人员作为对照组。应用流式细胞术检测B细胞血液肿瘤患者外周血淋巴细胞（Peripheral Blood Lymphocytes,PBL）CD40、CD154的表达率。结果 1MM组：CD40表达率为（17.50±8.32）%,CD154表达率为（1.00±3.26）%;B-NHL组：CD40表达率为（29.84±15.61）%,CD154表达率为（2.01±0.59）%;对照组：CD40表达率为（6.48±3.34）%,CD154表达率为（3.25±1.04）%。2化疗后B-NHL患者外周血淋巴细胞CD40表达低于化疗前,P〈0.05。3MM患者III期组PBLCD40表达率高于I~II期组,P〈0.05。B-NHL患者PBL CD154表达率III~IV期低于I~II期组,P〈0.05。结论 1MM患者、B-NHL患者均存在PBL CD40高表达,B-NHL患者同时存在PBL CD154低表达;CD40高表达提示MM预后差,CD154低表达与B-NHL预后有关。2化疗降低了B-NHL患者PBL CD40表达率。为临床上进行B细胞血液肿瘤诊断与治疗提供一定的依据。

Expression and Significance of CD40, CD154 in Patients with B-cell Hematologic Malignancies

Objective To analyze the characteristics of expression rate of peripheral blood lymphocytes （PBL） CD40 and CD154 in patients with B-cell hematologic malignancies. Methods 28 cases of patients with B-cell hematologic malignancies were divided into 17 cases with multiple myelom （MM） and 11 cases with B-cell non-Hodgkin＇s lymphoma （B-NHL）; 30 healthy people underwent healthy examination were selected as the control group. Flow cytometry was used to detect the expression rate of PBL CD40 and CD154 of patients with B-cell hematologic malignancies. Results 1. MM group： the expression rate of CD40 was （17.50 ±8.32）%, and that of CD154 was （1.00 ± 3.26）%; B-NHL group： the expression rate of CD40 was （29.84 ± 15.61）%, and that of CD154 was （2.01 ± 0.59）%; Control group： the expression rate of CD40 was （6.48 ± 3.34）%, and that of CD154 was （3.25 ± 1.04）%. 2.The expression rate of PBL CD40 of B-NHL patients after chemotherapy was lower than that before chemotherapy, P〈 0.05. 3.PBL CD40 expression rate of stage III subgroup in MM group was higher than that of stage I and stage II subgroups, P〈 0.05. PBL CD154 expression rate of stage III and IV subgroups in B-NHL group was lower than that of stage I and II subgroup, P〈0.05. ConehlSion 1. Patients with MM and patients with B-NHL had high expression of PBL CD40, and B-NHL patients also had low expression of PBL CD154; high expression of CD40 was associated with poor prognosis in patients with MM; low expression of CD154 was associated with poor prognosis in patients with B-NHL. 2. Chemotherapy reduced the expression rate of PBL CD40 in p~itients with B-NHL. It provides a basis for the diagnosis and treatment of B-cell hematologic malignancies.